71,501 Shares in Kenvue Inc. $KVUE Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 71,501 shares of the company’s stock, valued at approximately $1,366,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. boosted its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the period. Elyxium Wealth LLC acquired a new position in shares of Kenvue in the fourth quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new position in shares of Kenvue during the second quarter worth approximately $26,000. MV Capital Management Inc. bought a new position in shares of Kenvue during the fourth quarter worth approximately $28,000. Finally, CoreCap Advisors LLC lifted its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.4%

Shares of NYSE:KVUE opened at $19.34 on Wednesday. The business’s 50 day simple moving average is $19.10 and its 200 day simple moving average is $18.22. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $21.40. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The company has a market capitalization of $37.16 billion, a P/E ratio of 22.24, a P/E/G ratio of 1.39 and a beta of 0.47.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same period in the prior year, the firm earned $0.29 earnings per share. Kenvue’s revenue was up 3.0% on a year-over-year basis. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. The ex-dividend date is Wednesday, August 12th. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.3%. Kenvue’s dividend payout ratio is currently 96.55%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Barclays lifted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. UBS Group reduced their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.